The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows"

被引：1

作者：

Delcuratolo, Marco Donatello ^{[1
,5
]}

Crespi, Veronica ^{[2
,5
]}

Saba, Giorgio ^{[3
,4
,5
]}

Mogavero, Andrea ^{[5
]}

Napoli, Valerio Maria ^{[5
]}

Garbo, Edoardo ^{[5
]}

Cani, Massimiliano ^{[5
]}

Ungaro, Antonio ^{[6
]}

Reale, Maria Lucia ^{[7
]}

Merlini, Alessandra ^{[5
]}

Capelletto, Enrica ^{[5
]}

Bironzo, Paolo ^{[5
]}

Levis, Mario ^{[8
]}

Ricardi, Umberto ^{[8
]}

Novello, Silvia ^{[5
]}

Passiglia, Francesco ^{[5
]}

机构：

[1] Fdn IRCCS, Med Oncol Unit, Casa Sollievo Sofferenza, San Giovanni Rotondo, FG, Italy

[2] Asst Sette Laghi, Dept Med Oncol, Varese, Italy

[3] Univ Hosp, Med Oncol Unit, I-09042 Cagliari, Italy

[4] Univ Cagliari, I-09042 Cagliari, Italy

[5] Univ Turin, Dept Oncol, AOU S Luigi Gonzaga, Orbassano, TO, Italy

[6] San Giuseppe Moscati Hosp, Med Oncol Unit, Statte, TA, Italy

[7] Vito Fazzi Hosp, Med Oncol Unit, Lecce, Italy

[8] Univ Turin, Dept Oncol, Radiat Oncol Unit, AOU Citta Salute & Sci, Turin, Italy

来源：

CANCER TREATMENT REVIEWS | 2025年 / 135卷

关键词：

stage III; Locally advanced; Unresectable; Immunotherapy; Non-small cell lung cancer; WORLD TREATMENT PATTERNS; CIRCULATING TUMOR DNA; REAL-WORLD; CONCURRENT CHEMORADIOTHERAPY; CLINICAL-OUTCOMES; PHASE-III; PLUS CHEMOTHERAPY; PROGRESSION-FREE; DURVALUMAB; NSCLC;

D O I：

10.1016/j.ctrv.2025.102918

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite PACIFIC set a new milestone in the clinical management of unresectable stage III non-small cell lung cancer (NSCLC), it left some critical questions pending for clinical research: the efficacy of durvalumab in the real-world setting; the activity of less intensive regimens for frail populations; the role of targeted therapies in oncogene-addicted tumors; the selection of subsequent strategies at immunotherapy failure; the efficacy of novel and intensified treatments; the role of molecular biomarkers for patients' selection. This review aims to describe the evolving landscape of unresectable stage III NSCLC and provides an updated overview of the available evidence, analyzing lights and shadows emerging from recent clinical trials and discussing the most relevant challenges of post-PACIFIC era.

引用

页数：11

共 104 条

[91] Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer [J].

Wakelee, Heather ;

Liberman, Moishe ;

Kato, Terufumi ;

Tsuboi, Masahiro ;

Lee, Se-Hoon ;

Gao, Shugeng ;

Chen, Ke-Neng ;

Dooms, Christophe ;

Majem, Margarita ;

Eigendorff, Ekkehard ;

Martinengo, Gaston L. ;

Bylicki, Olivier ;

Rodriguez-Abreu, Delvys ;

Chaft, Jamie E. E. ;

Novello, Silvia ;

Yang, Jing ;

Keller, Steven M. M. ;

Samkari, Ayman ;

Spicer, Jonathan D. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (06) :491-503

[92] Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium [J].

Walraven, I. ;

Damhuis, R. A. ;

ten Berge, M. G. ;

Rosskamp, M. ;

van Eycken, L. ;

de Ruysscher, D. ;

Belderbos, J. S. A. .

CLINICAL ONCOLOGY, 2017, 29 (11) :E177-E185

[93] Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies [J].

Wang, Qiang ;

Ju, Xiaoli ;

Wang, Jiayou ;

Fan, Yu ;

Ren, Meijia ;

Zhang, Heng .

CANCER LETTERS, 2018, 438 :17-23

[94] Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures [J].

Wei, Feifei ;

Azuma, Koichi ;

Nakahara, Yoshiro ;

Saito, Haruhiro ;

Matsuo, Norikazu ;

Tagami, Tomoyuki ;

Kouro, Taku ;

Igarashi, Yuka ;

Tokito, Takaaki ;

Kato, Terufumi ;

Kondo, Tetsuro ;

Murakami, Shuji ;

Usui, Ryo ;

Himuro, Hidetomo ;

Horaguchi, Shun ;

Tsuji, Kayoko ;

Murotani, Kenta ;

Ban, Tatsuma ;

Tamura, Tomohiko ;

Miyagi, Yohei ;

Sasada, Tetsuro .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (07)

[95]

William Jr WN, 2024, J THORAC ONCOL, V19, pS37

[96]

Wu Y-L, PACIFIC-5: a Phase 3 Study of Consolidation Durvalumab in Patients with Unresectable Stage III NSCLC and No Progression After Concurrent or Sequential Chemoradiotherapy

[97] Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer [J].

Wu, Yi-Long ;

Dziadziuszko, Rafal ;

Ahn, Jin Seok ;

Barlesi, Fabrice ;

Nishio, Makoto ;

Lee, Dae Ho ;

Lee, Jong-Seok ;

Zhong, Wenzhao ;

Horinouchi, Hidehito ;

Mao, Weimin ;

Hochmair, Maximilian ;

de Marinis, Filippo ;

Migliorino, M. Rita ;

Bondarenko, Igor ;

Lu, Shun ;

Wang, Qun ;

Ochi Lohmann, Tania ;

Xu, Tingting ;

Cardona, Andres ;

Ruf, Thorsten ;

Noe, Johannes ;

Solomon, Benjamin J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14) :1265-1276

[98] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer [J].

Wu, Yi-Long ;

Tsuboi, Masahiro ;

He, Jie ;

John, Thomas ;

Grohe, Christian ;

Majem, Margarita ;

Goldman, Jonathan W. ;

Laktionov, Konstantin ;

Kim, Sang-We ;

Kato, Terufumi ;

Vu, Huu-Vinh ;

Lu, Shun ;

Lee, Kye-Young ;

Akewanlop, Charuwan ;

Yu, Chong-Jen ;

de Marinis, Filippo ;

Bonanno, Laura ;

Domine, Manuel ;

Shepherd, Frances A. ;

Zeng, Lingmin ;

Hodge, Rachel ;

Atasoy, Ajlan ;

Rukazenkov, Yuri ;

Herbst, Roy S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18) :1711-1723

[99] Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer [J].

Yoneda, Kazue ;

Kuwata, Taiji ;

Kanayama, Masatoshi ;

Mori, Masataka ;

Kawanami, Toshinori ;

Yatera, Kazuhiro ;

Ohguri, Takayuki ;

Hisaoka, Masanori ;

Nakayama, Toshiyuki ;

Tanaka, Fumihiro .

BRITISH JOURNAL OF CANCER, 2019, 121 (06) :490-496

[100] Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial [J].

Yue, D. ;

Wang, W. ;

Liu, H. ;

Chen, Q. ;

Chen, C. ;

Zhang, J. ;

Bai, F. ;

Wang, C. .

ANNALS OF ONCOLOGY, 2023, 34 :S1299-S1299

← 2 3 4 5 6 7 8 9 10 11 →